Journal ArticleOPEN ACCESS

Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma, Version 2.2024

JNCCN Journal of the National Comprehensive Cancer Network (2024) 22(1)
DOI: 10.6004/jnccn.2024.0001
18Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.

Cite

CITATION STYLE

APA

Kumar, S. K., Callander, N. S., Adekola, K., Md, Msci, Anderson, L. D., Baljevic, M., Baz, R., … Kumar, R. (2024). Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma, Version 2.2024. JNCCN Journal of the National Comprehensive Cancer Network, 22(1). https://doi.org/10.6004/jnccn.2024.0001

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free